BRING INNOVATION,
REALIZING GLOBAL POTENTIAL
“Bridging innovation to realize the global value
of pharmaceuticals.”
Global Mission
Established in January 2026. Leveraging extensive experience in the pharmaceutical business across Japan, the US, and Europe, we support your challenges in the global market. We provide practical insights into FDA applications, M&A, and cross-border management, deeply committing to maximizing our clients’ business value.
Core Competence
With a total of 44 years in the pharmaceutical industry (12 years in Japan + 32 years in the US), we offer advisory services from a management perspective grounded in practical expertise—ranging from the FDA orphan drug approval of Lidoderm to creating a global blockbuster.
Global Expansion
Furthermore, we support companies looking to expand from Japan into global markets, including Asia (China, India, etc.), the Middle East, and Europe.
Especially for companies seeking to open new markets in the US through drug discovery and development, we can work together to formulate regulatory pathways using Pre-IND, followed by marketability and development/sales strategies (in-house development or partnering). We look forward to consulting with you.
Representative Product Achievements
A global business achieving long-term success in over 50 countries
Lidoderm
Lidocaine 5% Patch
Obtained NDA approval as an orphan drug in the US in 1999. Sold in over 50 countries for 27 years, achieving cumulative sales of over 4 billion patches worldwide.
Representative Deals & Clients
Global Partners & Clients
🇺🇸 USA
- Becton, Dickinson and Company
- Bristol Myers Squibb
- Par Health (former Endo Pharmaceuticals)
- Hind Healthcare Litigation
- Federal Trade Commission Litigation
- Watson Pharmaceuticals Litigation
- Travanti M&A
- Eagle Pharmaceuticals
- Premier Research
🇪🇺 Europe
- Grünenthal
- IBSA
- Inno Pharma
🌏 Asia
- Mundi Pacific
- Mundi China
- ModiMundi
- Luoxin Pharmaceuticals
- EISAI China
- Link Health
- SK Chemicals
- CMS
- Linear Clinical Research
🇯🇵 Japan
- Eisai
- Fuji Pharma
Ichiro (Paul) Mori
Morient Pharma Advisory Inc.
Founder & President CEO
Possesses rare practical experience spanning 44 years in the pharmaceutical industry (12 years in Japan, 1981-1993; 32 years in the US, 1993-2025), achieving significant global business success.
Global Success Story
Lidoderm (Lidocaine 5% Patch), which received US NDA approval as an orphan drug in 1999, has been sold in over 50 countries. Over 27 years, it has achieved cumulative sales of over 4 billion patches, marking a global business success.
Current Innovation
Furthermore, currently developing a novel non-opioid analgesic patch in the US, which received Fast Track Designation from the FDA. Successfully completed P-2 (Proof of Concept) and is currently continuing P-2 for Agitation in dementia patients.
Morient Pharma Advisory Inc.
Founder & President CEO
(Executive Advisor : Teikoku Pharma USA, Teikoku Ventures Inc, TPU Pharma)
Teikoku Pharma USA
Executive Advisor / Chief Global Strategy Officer
Supported drug discovery pipelines, business alliances, and long-term growth strategies from management, development, and global strategy perspectives.
Teikoku Pharma USA (San Jose, CA)
President & CEO (2015-2024) / Co-Founder & COO (1997-2015)
Engaged in US-based management for 28 years. Led global business success as Co-Founder and later CEO.
Alpha Therapeutic Corp. (Los Angeles)
Associate Director, Regulatory
Regulatory Affairs for Biologics
Green Cross Corp. (Now Tanabe Pharma)
Sales Dept. / International Dept.
Joined after graduating from Kobe University, Faculty of Agriculture. Gained practical experience in Japan before moving base to the US in 1993.
Contact
Get in Touch
Phone Inquiry
+1-408-857-6464
(USA)